Literature DB >> 33721571

Transpupillary collagen photocrosslinking for targeted modulation of ocular biomechanics.

B G Gerberich1, B G Hannon2, A Hejri3, E J Winger3, E Schrader Echeverri1, L M Nichols3, H G Gersch1, N A MacLeod1, S Gupta4, A T Read1, M D Ritch1, S Sridhar1, M G Toothman1, G S Gershon1, S A Schwaner2, G Sánchez-Rodríguez1, V Goyal5, A M Toporek1, A J Feola6, H E Grossniklaus7, M T Pardue6, C R Ethier8, M R Prausnitz9.   

Abstract

The central vision-threatening event in glaucoma is dysfunction and loss of retinal ganglion cells (RGCs), thought to be promoted by local tissue deformations. Here, we sought to reduce tissue deformation near the optic nerve head by selectively stiffening the peripapillary sclera, i.e. the scleral region immediately adjacent to the optic nerve head. Previous scleral stiffening studies to treat glaucoma or myopia have used either pan-scleral stiffening (not regionally selective) or regionally selective stiffening with limited access to the posterior globe. We present a method for selectively stiffening the peripapillary sclera using a transpupillary annular light beam to activate methylene blue administered by retrobulbar injection. Unlike prior approaches to photocrosslinking in the eye, this approach avoids the damaging effects of ultraviolet light by employing red light. This targeted photocrosslinking approach successfully stiffened the peripapillary sclera at 6 weeks post-treatment, as measured by whole globe inflation testing. Specifically, strain was reduced by 47% when comparing treated vs. untreated sclera within the same eye (n = 7, p=0.0064) and by 54% when comparing the peripapillary sclera of treated vs. untreated eyes (n = 7, p<0.0001). Post-treatment characterization of RGCs (optic nerve axon counts/density, and grading), retinal function (electroretinography), and retinal histology revealed that photocrosslinking was associated with some ocular toxicity. We conclude that a transpupillary photocrosslinking approach enables selective scleral stiffening targeted to the peripapillary region that may be useful in future treatments of glaucoma.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Collagen photocrosslinking; Glaucoma; Methylene blue; Myopia; Ocular biomechanics; Scleral stiffening

Mesh:

Substances:

Year:  2021        PMID: 33721571      PMCID: PMC8044034          DOI: 10.1016/j.biomaterials.2021.120735

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  55 in total

1.  Expression and distribution of functional integrins in rat CNS glia.

Authors:  N J Tawil; P Wilson; S Carbonetto
Journal:  J Neurosci Res       Date:  1994-11-01       Impact factor: 4.164

2.  Scotopic and photopic components of the rat electroetinogram.

Authors:  D G Green
Journal:  J Physiol       Date:  1973-02       Impact factor: 5.182

3.  Genipin inhibits the scleral expression of miR-29 and MMP2 and promotes COL1A1 expression in myopic eyes of guinea pigs.

Authors:  Min Wang; Zhi-Kuan Yang; Hong Liu; Rui-Qin Li; Yu Liu; Wen-Jun Zhong
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2020-03-03       Impact factor: 3.117

Review 4.  Verteporfin: a milestone in opthalmology and photodynamic therapy.

Authors:  S B Brown; K J Mellish
Journal:  Expert Opin Pharmacother       Date:  2001-02       Impact factor: 3.889

Review 5.  Photodynamic therapy (PDT) of cancer: from local to systemic treatment.

Authors:  Janusz M Dąbrowski; Luis G Arnaut
Journal:  Photochem Photobiol Sci       Date:  2015-10       Impact factor: 3.982

6.  Immunolocalization of integrins in the human retina.

Authors:  R B Brem; S G Robbins; D J Wilson; L M O'Rourke; R N Mixon; J E Robertson; S R Planck; J T Rosenbaum
Journal:  Invest Ophthalmol Vis Sci       Date:  1994-08       Impact factor: 4.799

Review 7.  Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis.

Authors:  Yih-Chung Tham; Xiang Li; Tien Y Wong; Harry A Quigley; Tin Aung; Ching-Yu Cheng
Journal:  Ophthalmology       Date:  2014-06-26       Impact factor: 12.079

8.  Corneal crosslinking with genipin, comparison with UV-riboflavin in ex-vivo model.

Authors:  Marcel Y Avila; Vanessa A Gerena; Jose L Navia
Journal:  Mol Vis       Date:  2012-04-27       Impact factor: 2.367

9.  A comparison of hyperelastic constitutive models applicable to brain and fat tissues.

Authors:  L Angela Mihai; LiKang Chin; Paul A Janmey; Alain Goriely
Journal:  J R Soc Interface       Date:  2015-09-06       Impact factor: 4.118

10.  Targeted Drug Delivery in the Suprachoroidal Space by Swollen Hydrogel Pushing.

Authors:  Jae Hwan Jung; Patcharin Desit; Mark R Prausnitz
Journal:  Invest Ophthalmol Vis Sci       Date:  2018-04-01       Impact factor: 4.799

View more
  4 in total

1.  Evaluation of Spatially Targeted Scleral Stiffening on Neuroprotection in a Rat Model of Glaucoma.

Authors:  Brandon G Gerberich; Bailey G Hannon; Dillon M Brown; A Thomas Read; Matthew D Ritch; Elisa Schrader Echeverri; Lauren Nichols; Cahil Potnis; Sreesh Sridhar; Maya G Toothman; Stephen A Schwaner; Erin J Winger; Hannah Huang; Gabby S Gershon; Andrew J Feola; Machelle T Pardue; Mark R Prausnitz; C Ross Ethier
Journal:  Transl Vis Sci Technol       Date:  2022-05-02       Impact factor: 3.048

Review 2.  Glaucoma and biomechanics.

Authors:  Babak N Safa; Cydney A Wong; Jungmin Ha; C Ross Ethier
Journal:  Curr Opin Ophthalmol       Date:  2022-03-01       Impact factor: 3.761

3.  Corrigendum to "Using retinal function to define ischemic exclusion criteria for animal models of glaucoma" [Exp. Eye. Res. 202 (2021) 108354 doi: 10.1016/j.exer.2020.108354 Epub 2020 Nov 7].

Authors:  B G Hannon; A J Feola; B G Gerberich; A T Read; M R Prausnitz; C R Ethier; M T Pardue
Journal:  Exp Eye Res       Date:  2021-07-07       Impact factor: 3.770

Review 4.  Biomechanics of Ophthalmic Crosslinking.

Authors:  Brecken J Blackburn; Andrew M Rollins; William J Dupps
Journal:  Transl Vis Sci Technol       Date:  2021-04-29       Impact factor: 3.283

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.